CN102498110A - 作为激酶抑制剂的2-(lh-吡唑-4-基氨基)-嘧啶 - Google Patents

作为激酶抑制剂的2-(lh-吡唑-4-基氨基)-嘧啶 Download PDF

Info

Publication number
CN102498110A
CN102498110A CN2010800358308A CN201080035830A CN102498110A CN 102498110 A CN102498110 A CN 102498110A CN 2010800358308 A CN2010800358308 A CN 2010800358308A CN 201080035830 A CN201080035830 A CN 201080035830A CN 102498110 A CN102498110 A CN 102498110A
Authority
CN
China
Prior art keywords
amino
bases
pyrazoles
pyrimidine
formamides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800358308A
Other languages
English (en)
Chinese (zh)
Inventor
M·L·柯丁
M·R·麦克利德斯
H·R·海曼
R·R·弗里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CN102498110A publication Critical patent/CN102498110A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2010800358308A 2009-06-10 2010-06-08 作为激酶抑制剂的2-(lh-吡唑-4-基氨基)-嘧啶 Pending CN102498110A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18575809P 2009-06-10 2009-06-10
US61/185758 2009-06-10
PCT/US2010/037801 WO2010144468A1 (en) 2009-06-10 2010-06-08 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors

Publications (1)

Publication Number Publication Date
CN102498110A true CN102498110A (zh) 2012-06-13

Family

ID=42333314

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800358308A Pending CN102498110A (zh) 2009-06-10 2010-06-08 作为激酶抑制剂的2-(lh-吡唑-4-基氨基)-嘧啶

Country Status (7)

Country Link
US (1) US8426408B2 (enExample)
EP (1) EP2440548A1 (enExample)
JP (1) JP2012529522A (enExample)
CN (1) CN102498110A (enExample)
CA (1) CA2764983A1 (enExample)
MX (1) MX2011013325A (enExample)
WO (1) WO2010144468A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015039613A1 (zh) * 2013-09-18 2015-03-26 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
CN104926794A (zh) * 2014-03-17 2015-09-23 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
CN106588885A (zh) * 2016-11-10 2017-04-26 浙江大学 2‑取代芳环‑嘧啶类衍生物及制备和应用
WO2021078021A1 (zh) * 2019-10-24 2021-04-29 嘉兴特科罗生物科技有限公司 一种小分子化合物
CN118440052A (zh) * 2024-07-05 2024-08-06 四川大学 一种化合物及其在制备tyk2激酶抑制剂中的用途
WO2024179393A1 (zh) * 2023-02-27 2024-09-06 科辉智药(深圳)新药研究中心有限公司 亚砜酰亚胺化合物及其作为lrrk2蛋白激酶抑制剂的应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011260323A1 (en) 2010-06-04 2012-11-15 F. Hoffmann-La Roche Ag Aminopyrimidine derivatives as LRRK2 modulators
KR101566091B1 (ko) * 2010-11-10 2015-11-04 에프. 호프만-라 로슈 아게 Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체
TWI548621B (zh) * 2011-04-22 2016-09-11 標誌製藥公司 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法
CN104271569B (zh) * 2012-05-03 2016-08-24 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的吡唑氨基嘧啶衍生物
EP2976086B1 (en) * 2013-03-22 2020-10-14 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
US10273224B2 (en) 2013-08-22 2019-04-30 Jubilant Biosys Limited Substituted pyrimidine compounds, compositions and medicinal applications thereof
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
US9399637B2 (en) * 2014-03-28 2016-07-26 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
US10059689B2 (en) 2014-10-14 2018-08-28 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
US9513297B2 (en) 2014-12-16 2016-12-06 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
EP3712134B1 (en) 2014-12-16 2023-11-29 Signal Pharmaceuticals, LLC Salts of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
EP3250557B1 (en) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
EP3325432B1 (en) 2015-07-24 2020-09-02 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
US20170081338A1 (en) * 2015-09-17 2017-03-23 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
WO2019099311A1 (en) 2017-11-19 2019-05-23 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147831A1 (en) * 2007-05-23 2008-12-04 Smithkline Beecham Corporation Anthranilamides

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374301A (en) 1990-07-26 1994-12-20 Zeneca Limited Inks suitable for use in ink jet printing
GB9303912D0 (en) 1993-02-26 1993-04-14 Zeneca Ltd Inks
JP3880076B2 (ja) 1994-02-25 2007-02-14 キヤノン株式会社 インク、インクジェット記録方法、記録ユニット、インクカートリッジ及びインクジェット記録装置
JPH08113744A (ja) 1994-08-25 1996-05-07 Canon Inc インク、これを用いたインクジェット記録方法及びかかるインクを備えた記録機器
US6117996A (en) 1995-09-20 2000-09-12 Novo Nordisk A/S Triazine based ligands and use thereof
GB9519197D0 (en) 1995-09-20 1995-11-22 Affinity Chromatography Ltd Novel affinity ligands and their use
JP3106966B2 (ja) 1996-07-17 2000-11-06 富士ゼロックス株式会社 インクジェット記録用インク及びインクジェット記録方法
JPH1060338A (ja) 1996-08-21 1998-03-03 Fuji Xerox Co Ltd インクジェット記録用インク及びインクジェット記録方法
US5980623A (en) 1997-01-29 1999-11-09 Fuji Xerox Co., Ltd. Ink set for ink jet recording and ink jet recording method
JP3829419B2 (ja) 1997-07-09 2006-10-04 三菱化学株式会社 カラー画像の形成方法
WO2000038683A1 (en) 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
ATE542801T1 (de) * 2003-08-15 2012-02-15 Novartis Ag Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
JP4812763B2 (ja) 2004-05-18 2011-11-09 ライジェル ファーマシューティカルズ， インコーポレイテッド シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途
ATE554087T1 (de) 2004-10-29 2012-05-15 Abbott Lab Neue kinaseinhibitoren
GB2420559B (en) 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
MX2007005857A (es) * 2004-11-17 2007-10-10 Mikana Therapeutics Inc Inhibidores de cinasa.
US8211929B2 (en) * 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
JPWO2006126718A1 (ja) 2005-05-27 2008-12-25 田辺三菱製薬株式会社 ピラゾロピリミジン誘導体
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2006131768A2 (en) 2005-06-10 2006-12-14 Prometic Biosciences Limited Triazines as protein binding ligands
US20070032514A1 (en) 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147831A1 (en) * 2007-05-23 2008-12-04 Smithkline Beecham Corporation Anthranilamides

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015039613A1 (zh) * 2013-09-18 2015-03-26 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
CN104926794A (zh) * 2014-03-17 2015-09-23 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
CN104926824A (zh) * 2014-03-17 2015-09-23 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
CN104926795A (zh) * 2014-03-17 2015-09-23 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
CN104926824B (zh) * 2014-03-17 2017-07-07 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
CN104926794B (zh) * 2014-03-17 2017-12-05 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
CN106588885A (zh) * 2016-11-10 2017-04-26 浙江大学 2‑取代芳环‑嘧啶类衍生物及制备和应用
WO2018086547A1 (zh) * 2016-11-10 2018-05-17 浙江大学 2-取代芳环-嘧啶类衍生物及制备和应用
CN106588885B (zh) * 2016-11-10 2019-03-19 浙江大学 2-取代芳环-嘧啶类衍生物及制备和应用
WO2021078021A1 (zh) * 2019-10-24 2021-04-29 嘉兴特科罗生物科技有限公司 一种小分子化合物
WO2024179393A1 (zh) * 2023-02-27 2024-09-06 科辉智药(深圳)新药研究中心有限公司 亚砜酰亚胺化合物及其作为lrrk2蛋白激酶抑制剂的应用
CN118440052A (zh) * 2024-07-05 2024-08-06 四川大学 一种化合物及其在制备tyk2激酶抑制剂中的用途

Also Published As

Publication number Publication date
US20100317680A1 (en) 2010-12-16
US8426408B2 (en) 2013-04-23
WO2010144468A1 (en) 2010-12-16
MX2011013325A (es) 2012-04-30
JP2012529522A (ja) 2012-11-22
CA2764983A1 (en) 2010-12-16
EP2440548A1 (en) 2012-04-18

Similar Documents

Publication Publication Date Title
US8293738B2 (en) Indazole inhibitors of kinase
US8426408B2 (en) Pyrimidine inhibitors of kinases
TWI500621B (zh) 具改良ｃｙｐ安全性之激酶抑制劑
US9718821B2 (en) Pyridopyrimidinone inhibitors of kinases
CN103415516A (zh) Alk的双环抑制剂
MX2012013196A (es) Inhibidores de pirrolopiridina y pirrolopirimidina de cinasas.
KR20110102473A (ko) 헤테로시클릭 화합물 및 사용 방법
CN102459236B (zh) 激酶活性的嘧啶抑制剂
JP2014530867A (ja) キナーゼのピリドピリミジノン阻害剤
US8859546B2 (en) Picolinamide inhibitors of kinases
US9212192B2 (en) Bicyclic carboxamide inhibitors of kinases
CN109422749A (zh) 一种抑制单羧酸转运蛋白的嘧啶二酮衍生物
US8436179B2 (en) Kinase inhibitor with improved solubility profile
NZ623068A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ABBVIE COMPANY

Free format text: FORMER OWNER: ABBOTT GMBH. + CO. KG

Effective date: 20130618

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130618

Address after: Illinois State

Applicant after: ABBVIE company

Address before: Illinois State

Applicant before: Abbott GmbH. & Co. Kg

AD01 Patent right deemed abandoned

Effective date of abandoning: 20120613

C20 Patent right or utility model deemed to be abandoned or is abandoned